Biofrontera Inc. (BFRIW) Stock Ticker
Market factors today
Unlock the full BFRIW picture
About Biofrontera Inc.
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.
BFRIW stock facts
| Ticker symbol | BFRIW |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Market cap | $11.4M |
| CEO | Hermann Lübbert |
| Employees | 92 |
| Headquarters | Woburn, MA, US |
| IPO date | 2021-10-29 |
| Website | www.biofrontera-us.com |
What you can see for BFRIW on Tickr
Live BFRIW price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BFRIW report.
Rankings
FAQ
What is the ticker symbol for Biofrontera Inc.?
The ticker symbol for Biofrontera Inc. is BFRIW, listed on the NASDAQ Capital Market.
What is BFRIW?
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis…